Diabetes & cardiovascular risk reduction
Cardiometabolic prevention · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Type 2 diabetes markedly increases atherosclerotic and heart-failure risk. Contemporary management prioritises cardiovascular and renal protection using SGLT2 inhibitors and GLP-1 receptor agonists alongside lipid, blood-pressure and antiplatelet therapy.
Red flags
- Symptoms of myocardial ischaemia
- Heart failure signs (dyspnoea, oedema)
- Rapidly rising albuminuria or falling eGFR
- Euglycaemic ketoacidosis on SGLT2 inhibitor
- Foot ulceration or critical limb ischaemia
Assessment
Differential diagnosis
- Type 2 diabetes with ASCVD
- Diabetes with heart failure
- Diabetes with chronic kidney disease
- Metabolic syndrome without diabetes
- Type 1 diabetes with CV risk
- Secondary diabetes
Investigations
- HbA1c and renal function (eGFR, urine ACR)
- Lipid profile
- Blood pressure assessment
- ECG and symptom review for CAD/HF
- NT-proBNP or echo if heart failure suspected
- Foot and retinal screening for microvascular disease
Management
- Assess global cardiovascular and renal risk, not just glycaemia
- Start an SGLT2 inhibitor for patients with ASCVD, heart failure or CKD regardless of HbA1c
- Add a GLP-1 receptor agonist for established or high ASCVD risk, especially with obesity
- Set an individualised HbA1c target (commonly ~53 mmol/mol / 7%)
- Prescribe a statin for cardiovascular risk and titrate to LDL target
- Control blood pressure, favouring ACEi/ARB with albuminuria
- Use aspirin only for secondary prevention, not routine primary prevention
- Reinforce weight management, diet, exercise and smoking cessation
- Monitor renal function after starting SGLT2 inhibitor or RAAS blockade
- Counsel on sick-day rules and euglycaemic DKA risk with SGLT2 inhibitors
- Screen for and manage heart failure and CKD progression
- Arrange structured multidisciplinary follow-up
Drugs & doses
Empagliflozin 10 mg PO OD (or dapagliflozin 10 mg OD) — SGLT2 inhibitor
Semaglutide SC titrated (or oral semaglutide) — GLP-1 receptor agonist
Atorvastatin 20-80 mg PO OD for lipid lowering
Ramipril 2.5-10 mg PO OD (with albuminuria/hypertension)
Metformin 500-1000 mg PO BD as glucose-lowering foundation
Disposition
GP and diabetes team shared care; cardiology/nephrology referral for established heart failure or progressive CKD.
Complications & pitfalls
- Atherosclerotic cardiovascular events
- Heart failure
- Chronic kidney disease progression
- Euglycaemic diabetic ketoacidosis (SGLT2i)
- Hypoglycaemia from other agents
Exam pearls
- SGLT2 inhibitors and GLP-1 agonists reduce cardiovascular events independent of glucose lowering
- Choose the agent by the dominant risk: SGLT2i for HF/CKD, GLP-1 for atherosclerotic risk/obesity
- Aspirin is not recommended for routine primary prevention in diabetes
- Counsel on SGLT2-inhibitor sick-day rules to prevent euglycaemic DKA
- Renal and cardiovascular protection now drives drug choice more than HbA1c
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.